KALC 2026

Sponsorship Opportunities

Deadline

Deadline
신청기한	7월 31일(금)까지

Sponsorship Packages

※ 10% VAT 별도

Sponsorship Packages
구분		등급		Diamond	Platinum	Gold	Silver	Bronze	Standard
구분		제공사항 및 금액		₩150,000,000	₩100,000,000	₩70,000,000	₩30,000,000	₩10,000,000	₩5,000,000
전시 부스		전시부스 위치 선정 • 동등급 후원사 신청순으로 우선배정		1순위	2순위	3순위	4순위	5순위	6순위
전시 부스		부스 공간 제공 (3m*2m) • 대회장 상황에 따라 연속부스 불가능할 수 있음 • 부득이한 경우, 조직위원회와 상의 후 제공되는 부스 공간 조정될 수 있음		3 부스	3 부스	2 부스	2 부스	1 부스	1 부스
등록		무료등록 (런치쿠폰 포함) • 후원사 임직원에 한하며, 명찰의 소속은 후원사 영문명으로 인쇄됨		12EA	10EA	7EA	5EA	3EA	2EA
등록		Faculty Dinner 후원사 대표 초청		2명	2명	2명	1명	-	-
Program		Luncheon Symposium • 동등급 후원사 신청순으로 우선배정	Noon (1)	O
		Satellite Symposium • 동등급 후원사 신청순으로 우선배정	Afternoon (2)		O
		Satellite Symposium • 동등급 후원사 신청순으로 우선배정	Morning (2)			O
온라인 홍보		대회 홈페이지 로고 노출 - 메인페이지 하단		O	O	O	O	O	-
		대회 홈페이지 로고 노출 - 후원페이지		O	O	O	O	O	-
		대회 뉴스레터 로고 노출 - 하단 • 후원 등급 별 로고 크기 상이		O	O	O	O	O	-
		대회 뉴스레터 Luncheon & Satellite Symposium 광고		O	O	O	-	-	-
현장 홍보	제작물	명찰 줄 로고 인쇄		O	-	-	-	-	-
		Congress KIT 로고 삽입 • 대회 상황에 따라 변동될 수 있음		O	-	-	-	-	-
		현황판 로고 삽입		O	O	O	-	-	-
		등록데스크 로고 삽입		O	O	O	-	-	-
		포토존 로고 삽입		O	O	O	-	-	-
		카페라운지 로고 삽입		O	O	O	-	-	-
		포스터 번호표 로고 삽입		O	O	-	-	-	-
	책자광고	프로그램 북(Printed book) 내지광고		1 페이지	1 페이지	1 페이지	1 페이지	1 페이지	별도 추가신청
	책자광고	초록집(e-book) 내지광고		2 페이지	1 페이지	1 페이지	1 페이지	1 페이지	별도 추가신청
	Break 시 후원사 홍보 영상 상영			2분	1분	-	-	-	-

프로그램 북 & 초록집 광고

※ 10% VAT 별도

Program Book & Abstract Book
구분	광고	금액 (VAT 별도)
프로그램북	표4	₩2,000,000
	표2	₩1,500,000
	표3	₩1,000,000
	내지	₩700,000
초록집(e-book)	내지	₩700,000

Inquiry.

KALC 2026 secretariat (kalcic@lungca.or.kr / +82-2-6411-7378)

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0047	14:45-14:55	Lung Cancer Screening in Korean Women Who Have Never Smoked with a Family History of Lung Cancer: The NIKE Study	So Yeon (lydia) Kim	Samsung Medical Center	Korea
A-0106	14:55-15:05	Beyond Solid Size: Favorable Prognostic Value of Ground-Glass Opacity in Stage IA Lung Adenocarcinoma	Sung Goo Park	Samsung Medical Center	Korea
A-0212	15:05-15:15	Cardio-Oncology Clinic Involvement and Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Receiving Targeted Therapy	Hyukjin Park	Chonnam National Univ.	Korea
A-0183	15:15-15:25	Real-World Outcomes of Neoadjuvant Immunotherapy versus Definitive Chemoradiotherapy with Durvalumab Consolidation in Stage III Non-Small Cell Lung Cancer	Hye In Lee	Seoul National Univ.	Korea
A-0091	15:25-15:35	Interim Analysis of Camrelizumab Plus Pemetrexed and Carboplatin in Advanced Non-Squamous NSCLC	Juwhan Choi	Korea Univ.	Korea
A-0017	15:35-15:45	Autologous Vax-NK Consolidation Therapy in ES-SCLC: Identification of Predictive Biomarkers via High-Dimensional Circulating Immune Cell Profiling	Sung-Woo Lee	Chonnam National Univ.	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0207	09:10-09:20	Patient-Specific Lung Cancer Tumoroids for Studying Tumor-Stroma-Immune Interactions and Personalized Immuno-Oncology	Yoo Ri Ko	Asan Medical Center	Korea
A-0118	09:20-09:30	Unbiased Transcriptome-Derived AI Classification of Tertiary Lymphoid Structures on H&E Images Predicts Survival and Immune Microenvironment in NSCLC	Jaeyoon Lee	Northwestern Univ.	Korea
A-0097	09:30-09:40	Prognostic Impact of Spread Through Air Spaces and Optimal Surgical Extent in Stage I NSCLC after Sublobar Resection	Sangil Yun	Seoul National Univ.	Korea
A-0134	09:40-09:50	Phenotype-Dependent Nonlinear Associations Between Tumor Size and Aggressive Histologic Features in Lung Adenocarcinoma	Hyojin Kim	Seoul National Univ.	Korea
A-0100	09:50-10:00	Beyond Major Pathological Response: Favorable Pathological Response Improves Risk Stratification After Neoadjuvant Chemoimmunotherapy for Resectable NSCLC	Hsiang Teng	Tri-Service General Hospital	Taiwan
A-0057	10:00-10:10	Pathologic Response in Lymph Nodes after Neoadjuvant Therapy in NSCLC: Tumor Bed Extent, Not VT%, Drives Survival Associations	Sungjin Kim	Seoul National Univ.	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0033	PE1-01	Designing Novel Therapy for Lung Cancer using Monobody Scaffolds Targeting EGFR	Tushar Kushwaha	All India Institute Of Medical Sciences	India
A-0056	PE1-02	Mutational Profiling and Network Analysis of Circulating Cell-Free DNA in Chemical Carcinogen-Induced Murine Lung Cancer Models	Saumya Patel	Gujarat University	India
A-0088	PE1-03	Optimizing Intraoperative STAS Prediction in Stage IA Lung Adenocarcinoma: Composite Rule Integrating Frozen and CT Findings	Yeon Bi Han	Seoul National University Bundang Hospital	Korea
A-0132	PE1-04	Inflammation Meets Matrix Remodeling: NF-kB and MMP-3 Signatures in COPD-Associated Lung Carcinogenesis	Isura Febrihartati	University of Lampung	Indonesia
A-0028	PE1-05	DNA Methylation Evaluation in Blood-Derived Cell-Free DNA as an Approach to Identify Biomarkers for the Early-Stage Lung Cancer Diagnosis	Deep Raj Yadav	King George's Medical University	India
A-0063	PE1-06	Translational Evaluation of 2 beta-Hydroxybetulinic Acid 3-Oleiate Against EGFR/KRAS-Driven Redox-Metabolic Vulnerabilities in Non-Small Cell Lung Cancer	Danish Ahmed	Sam Higginbottom University Of Agriculture, Technology And Sciences	India
A-0060	PE1-07	Restoring Mitochondrial Apoptosis in Non-Small Cell Lung Cancer Through Pharmacoinformatic Modulation of the STAT3/MCL-1 Axis	Rizki Rachmad Saputra	Universitas Palangka Raya	Indonesia
A-0067	PE1-08	Transcriptomic Analysis of Glycyrrhiza glabra (Licorice) Derived microRNAs and Their Cross-Kingdom Regulatory Potential in Lung Carcinoma	Mitsu Patel	Gujarat University	India
A-0074	PE1-09	Aloesin inhibits lung cancer metastasis, apoptosis and proliferation by modulating the JAK/STAT3 signaling pathway	N Singh	Csvtu, Bhilai	India
A-0073	PE1-10	Curcumin-Loaded Hybrid Polymeric Nanoparticles Inhibit Diethylnitrosamine (DEN) and 2-acetylaminofluorene -Induced Lung Carcinogenesis via Modulation of EGFR and Apoptosis	Deepika Singh	Shuats	India
A-0071	PE1-11	Revesterol Encapsulated Solid Lipid Nanoparticles Inhibit the Diethylnitrosamine/2-Acetylaminofluorene Induced Lung Cancer by modulating Apoptosis and Suppressing Proliferation	Deepika Singh	Shuats	India
A-0069	PE1-12	Application of Machine Learning and Artificial Intelligence for Prediction of Lung Cancer Risk in Central India	Manvendra Singh	Hmfa Miet	India
A-0078	PE1-13	Efficacy Evaluation of Circulating Tumor Cells Enrichment Platforms in Advanced Lung Cancer: A Pilot Study	Jae Heun Chung	Pusan National University Yangsan Hospital	Korea
A-0081	PE1-14	Development of an Orthotopic Mouse Model for Spread Through Air Space in EGFR E19del NSCLC with Gefitinib Resistance	Sungjin Kim	Seoul National University Bundang Hospital	Korea
A-0144	PE1-15	Engineered PterostilbeneChitosan Nanoparticles Combat Benzopyrene-Induced Lung Cancer through Alteration of HO-1/Nrf2 Signaling Pathway	D Chauhan	Rajkamal Science & Management College	India
A-0140	PE1-16	Umbelliferone-Chitosan nanobeads ameliorate Diethylnitrosamine induced Lung Carcinogenesis in rats via alteration of Nrf-2/HO-1 and PI3K/AKT/NF-B signaling pathway	V Kumar	Shalom Institute Of Health & Allied Sciences	India
A-0128	PE1-17	Ganoderic Acid-Chitosan Lipid Nanoparticles Attenuate Benzopyrene-Induced Lung Cancer via Alteration of PI3K/Akt/mTOR, NF-B and MAPK/ERK Signaling Pathway	Vikas Kumar	Sam Higginbottom University Of Agriculture, Technology & Sciences	India
A-0127	PE1-18	Clinicopathologic correlates of TTF-1 expression pattern in differentiated lung adenocarcinoma	Heae Surng Park	Ewha Womans University Medical Center	Korea
A-0125	PE1-19	Transcriptomic Deconvolution of Non-Small Cell Lung Cancer Resection Margins Identifies a 5-Gene Signature Predicting Post-Lobectomy Recurrence	Hafsa Riaz	Islamic University Of Indonesia	Pakistan
A-0123	PE1-20	Patient-Derived Organoids Reveal Tumor Heterogeneity and Plasticity Underlying Drug Resistance in Lung Squamous Cell Carcinoma	Ji Eun Park	Gwangju Institute of Science and Technology	Korea
A-0122	PE1-21	Comparative Analysis of Bronchoalveolar Lavage Fluid-Derived Exosomal microRNA Profiles between Early-Stage and Advanced-Stage Non-Small Cell Lung Cancer	Hyerin Kang	Dongtan Sacred Heart Hospital	Korea
A-0165	PE1-22	Coexisting ALK Rearrangement, EGFR L858R Mutation, and Germline BRIP1 Variant in Lung Adenocarcinoma With Durable Response to Alectinib	Priscillia Imelda	Dharmais Cancer Hospital, National Cancer Center, Indonesia	Indonesia
A-0163	PE1-23	Claudin 18.2 as a Specific Diagnostic Marker for Pulmonary Invasive Mucinous Adenocarcinoma	Jungsup Byun	Daegu Fatima Hospital	Korea
A-0167	PE1-24	Targeting the PARP1/SRC Axis Associated with DNA Repair and Metastatic Progression in NSCLC: Pharmacoinformatic Study of Xylaria sp. Metabolites	Rizki Rachmad Saputra	Universitas Palangka Raya	Indonesia
A-0174	PE1-25	Quercetin and Vitexin as Multi-Target Inhibitors of KRAS, ALK, and BRAF in NSCLC	Kajal Arora	Galgotias University	India
A-0179	PE1-26	Integrated Bioinformatics Analysis For Identification Of Key Metabolic Hub Genes In Lung Cancer	Sahil Arora	Sharda University	India
A-0192	PE1-27	Platelet Indices as Prognostic Biomarkers in Lung Cancer: An Updated Systematic Review and Dose Response Meta-analysis	Ahmed Almezaine	Ministry of Health	Egypt
A-0186	PE1-28	Differences in the Risk Association of TERT rs2736098 with Lung Cancer Between Two Ethnic People from Different Ancestry: A Meta-Analysis	Farhana Sultana Mitu	Islamic University	Bangladesh
A-0185	PE1-29	A Meta-Analytic Approach to Identify the Association Between p73 rs2273953 to rs1801173 Polymorphism and Risk of Lung Cancer	Md Abdullah Al Maruf	Islamic University	Bangladesh
A-0182	PE1-30	SUMOylation-Mediated SHMT2 Degradation by WYC209 Reverses Osimertinib Resistance through Serine-Glycine Pathway Disruption in Lung Cancer	Jiaxuan Xu	Nanjing University of Chinese Medicine	China
A-0209	PE1-31	CTSC promotes malignant phenotypes and maintains autophagy-related machinery through a YAP-dependent ATG5/ATG7 axis in small cell lung cancer	Nayoung Kim	Chungnam National University	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0050	PE1-32	Extended CT Surveillance Beyond 5 Years and Outcomes in Long-term Lung Cancer Survivors	Dong Woog Yoon	Samsung Medical Center	Korea
A-0098	PE1-33	Predicting Lung Cancer Risk Using Machine Learning Models on an Open Clinical Dataset: A Comparative Study	Lambe Teddy	Pokoknya Ada Medical Research Institute	Indonesia
A-0171	PE1-34	Impact of Metabolic Syndrome on Risk of Lung Cancer Among Korean Never-Smokers: A Nationwide Population-Based Cohort Study	Dongwon Park	Shihwa Medical Center	Korea
A-0014	PE1-35	Circulating Small Extracellular Vesicle miRNAs as Diagnostic Biomarkers for NSCLC: A Sequencing and Validation Study	Kamal Baswal	Aiims New Delhi	India
A-0086	PE1-36	Automated RECIST-Guided Longitudinal Lesion Tracking on a Per-Timepoint Annotated Thoracic CT Cohort: A Pilot Study	Jin Lee	Chonnam National University	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0187	PE1-37	Platelet Indices as Prognostic Biomarkers in Lung Cancer: A Meta-Analysis	Md Abdullah Al Maruf	Islamic University	Bangladesh
A-0026	PE1-38	A Rare Case Report: Type III Pleuropulmonary Blastoma in a Child with DICER1 Syndrome	Chew Way Jin	University Malaya Medical Center (PPUM)	Malaysia

Pulmonology / Endoscopy
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0087	PE1-39	Better Clot Prevention, Greater Bleeding Risk? Optimizing Cancer-Associated Thromboprophylaxis with DOACs Versus LMWH: A Systematic Review and Meta-Analysis	Lutfi Hafiz Zunardi	Sunan Kalijaga General Hospital	Indonesia
A-0154	PE1-40	Intratumoral Cisplatin For Primary And Metastatic Lung Tumors: A Systematic Review	Vince Nigel Blanco	St. Luke's Medical Center	Philippines

Radiology / Staging / Screening / Epidemiology
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0200	PE1-41	Discontinuation of Lung Cancer Clinical Studies: A Cross-Sectional Analysis	Yousef Radwan Alnomani	Faculty Of Medicine, Benha University	Egypt
A-0221	PE1-42	Provincial Burden of Lung Cancer Mortality Attributable to Active and Secondhand Smoking Across Indonesia	Zulfania Rahmah	Al Aziz Hospital	Indonesia
A-0220	PE1-43	Three Decades of Lung Cancer DALYs in Southeast Asia: Temporal Trends and Geographic Variation	Nazala Safira	Universitas Islam Indonesia	Indonesia
A-0206	PE1-44	Spatial Distribution of Lung Cancer Disability-Adjusted Life Years and Associated Risk Factors Among Adults Aged 2054 Years in Indonesia	Nazala Safira	Universitas Islam Indonesia	Indonesia
A-0034	PE1-45	Diagnostic Test of an Integrated Immuno-Nutritional Scoring System (INSS) to Differentiate Lung Cancer from Pulmonary Tuberculosis in Resource-Limited Settings	Muhamad Ramdani Ibnu Taufik	Cakra Husada Hospital	Indonesia
A-0052	PE1-46	Clinical and Epidemiologic Profile and Predictors of Advanced-Stage Disease Among Filipino Female Never-Smokers with Lung Adenocarcinoma: An Analytical Cross-Sectional Study	Vince Nigel Blanco	St. Luke's Medical Center	Philippines
A-0068	PE1-47	Development of a Loop-Mediated Isothermal Amplification Assay for EML4-ALK Variant 1 Detection	Ferdinand Mira	Ateneo De Manila University	Philippines
A-0099	PE1-48	Association Between Household Cooking Fuel Type and Chronic Respiratory Symptoms Among Never-Smoking Indonesian Adults	Lambe Teddy	Pokoknya Ada Medical Research Institute	Indonesia
A-0130	PE1-49	Public Acceptability of Expanding National Lung Cancer Screening Eligibility in South Korea: A Nationwide Survey	Jegu Kang	National Cancer Center	Korea
A-0121	PE1-50	Impact of an Artificial Intelligence Integrated Computer Aided Quality Control System on Screening Accuracy in Korean National Lung Cancer Screening	Ji-Youn Song	National Cancer Center	Korea
A-0119	PE1-51	Participation Rates and Screening Outcomes of the National Organized Population- Based Lung Cancer Screening Program in Korea	National Cancer Center	Korea
A-0153	PE1-52	Regional Variations in Young-Onset Lung Cancer Burden Across Java Island: Insights from Five-Year Global Burden of Disease Analysis	Cindy Ayudia Pramaesti	Kustati Hospital	Indonesia
A-0172	PE1-53	Trends in the Burden of Tracheal, Bronchus, and Lung Cancer in Indonesia, 1990 to 2023: Insights From GBD 2023	Adi Nugraha	Rsui Banyubening Boyolali	Indonesia
A-0198	PE1-54	Development and Validation of a Prognostic Model for Lung Cancer-Specific Survival Following Surgical Resection: A Population-Based study	Ahmed Ghait	Ministry of Health	Egypt
A-0193	PE1-55	Racial and Ethnic Disparities in Surgical Management of Early-Stage Non-Small Cell Lung Cancer: A Population Based Study	Ahmed Almezaine	Ministry of Health	Egypt
A-0217	PE1-56	Artificial Intelligence for CT-Based Pulmonary Nodule Detection and Lung Cancer Risk Stratification	Maha Fatima	National Cancer Center	Korea
A-0204	PE1-57	Association Between Dietary Inflammatory Index and Lung Cancer Risk: A Systematic Review and Meta-Analysis	Amir Hegazi	Mansoura University	Egypt

Early / Locally Advanced Non-Small Cell Lung Cancer
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0008	PE2-01	First-Line Afatinib in Uncommon EGFR-Mutant Stage IV NSCLC: Real-World Outcomes	Anh Nguyen	Hanoi Medical University	Vietnam
A-0037	PE2-02	Clinical Outcomes and Pathological Characteristics of Surgically Resected EGFR-mutant Non-small Cell Lung Cancer According to the Consolidation-to-tumor Ratio: Case-control Study	Taehun Kim	Keimyung University Dongsan Medical Center	Korea
A-0158	PE2-03	Resistance Mechanisms and Secondary Mutations Following Third-Generation EGFR Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-Analysis	Nabila Nurisma	Faculty of Medicine Universitas Indonesia	Indonesia
A-0162	PE2-04	Chemo-immunotherapy and Surgical Completion in Resectable Non-Small Cell Lung Carcinoma: A TriNetX Study of 11,572 Matched Patients	Ahmed Elaraby	Al-Azhar University	Egypt
A-0009	PE2-05	Real-World Survival Outcomes of Afatinib in Advanced NSCLC Patients with Major Uncommon EGFR Mutations: A Subgroup Analysis of G719X	Anh Nguyen	Hanoi Medical University	Vietnam
A-0051	PE2-06	Brain Metastases After Lung Adenocarcinoma Surgery: Safer with Neoadjuvant or Adjuvant Chemotherapy? A Nationwide Registry Analysis	Nisrina Nabila	Universitas Islam Indonesia	Indonesia
A-0077	PE2-07	Treatment Preferences for Stage II NSCLC in Korea: A Cross-Sectional Survey on Upfront Surgery versus Neoadjuvant Therapy	Jiwon Kwak	Samsung Medical Center	Korea
A-0085	PE2-08	High Level of Preoperative NK Cell Activity Predicts Delay of Recurrence in Surgically Resected Lung Cancer	Seung Hyeun Lee	Kyung Hee University	Korea
A-0105	PE2-09	Divergent EMT Regulation in the Tumor-Adjacent Microenvironment Drives Prognostic Divergence in GGO and Solid Lung Adenocarcinoma	Han Sanghyun	Chungbuk National University	Korea
A-0101	PE2-10	Sequential Targeted Therapy and Immunotherapy in NSCLC: A FAERS Analysis Reveals Increased Risk of Severe and Fatal Pneumonitis	Ekram Hasanin	University of Tripoli	Libyan Arab Jamahiriya

Mesothelioma / Thymic & Other Thoracic Malignancies
Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0146	PE2-11	Surgical Resection of Residual Mediastinal Masses After Induction Chemotherapy for Primary Mediastinal Non-Seminomatous Germ Cell Tumors	Parvin Akhmedov	The Loginov Moscow Clinical Scientific Center	Russian Federation
A-0156	PE2-12	Integrative Bioinformatic Analysis of Personalized Malignant Suppression with Deoxypodophyllotoxin in Pleural Mesothelioma Patients	Anindya Amanda Damayanti	Medaeng Public Health Center	Indonesia
A-0219	PE2-13	The Only High-Income Country With a Rising Mesothelioma Trend: A Nationwide Prospective Cohort Study From South Korea	Kwanyong Hyun	The Catholic University of Korea St. Vincent's Hospital	Korea
A-0191	PE2-14	Turning Clinical Challenges into Treatment Opportunities: The Role of MDT in Mediastinal Solitary Fibrous Tumour	Chan Teng Chong	National Cancer Institute	Malaysia